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Abstract 
Clinically effective therapies now exist for remission maintenance in both ulcerative colitis [UC] and 
Crohn's Disease [CD]. For each major class of IBD medications [5-aminosalicyclates, 
immunomodulators, and biologic agents], used alone or in combination, there is a risk of relapse 
following reduction or cessation of treatment. A consensus expert panel convened by the European 
Crohn's and Colitis Organisation [ECCO] reviewed the published literature and agreed a series of 
consensus practice points. The objective of the expert consensus is to provide evidence-based 
guidance for clinical practice so that physicians can make informed decisions in partnership with their 
patients. The likelihood of relapse with stopping each class of IBD medication is reviewed. Factors 
associated with an altered risk of relapse with withdrawal are evaluated, and strategies to monitor and 
allow early identification of relapse are considered. In general, patients in clinical, biochemical, and 
endoscopic remission are more likely to remain well when treatments are stopped. Reintroduction of 
the same treatment is usually, but not always, successful. The decision to stop a treatment needs to 
be individualized, and shared decision making with the patient should take place. 
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1.  INTRODUCTION 
Whereas there is an emerging consensus on the optimal approach to initiation of a range of therapies 
in inflammatory bowel disease [IBD], there remains greater uncertainty about the risks, benefits, and 
timing of stopping treatment when patients are in stable remission on therapy. It is therefore timely to 
review the current evidence about the risks of disease relapse [balanced against the risks and costs of 
continued treatment] associated with withdrawal of the agents commonly used for remission 
maintenance in both ulcerative colitis [UC] and Crohn's disease [CD]. The risk/benefit ratio of stopping 
differs depending on whether patients are receiving either 5-amino-salicylates [5ASA], 
immunomodulators [IM] or biologic therapies such as tumour necrosis factor inhibitors [TNFi] either 
alone or in combination. Patients often wish to stop or reduce treatment if there are not undue risks. 
The challenge involved in getting an individual patient back into remission and the likelihood of 
successful re-treatment with the same or other drugs are key considerations. Treatment costs 
associated with indefinite maintenance therapy are also considerable, and some toxicity of treatment 
may be related to the cumulative duration of exposure to treatment. This is particularly important given 
that sustained treatment with certain drugs such as thiopurines has been associated with a convincing 
increase in the risk of cancers such as lymphoma, non-melanoma skin cancer, myeloproliferative 
disorders, and urothelial cancers.
1-4
 The objective of the expert consensus is therefore to provide 
evidence-based guidance for clinical practice so that physicians can make informed decisions, in 
partnership with their patients, about the optimal exit strategy from treatment. 
 
2.  METHODS 
The European Crohn's and Colitis Organisation [ECCO] set up a topical review consensus group on 
the issue of treatment withdrawal ['exit strategies']. ECCO topical reviews result from expert opinion 
consensus and are endorsed by ECCO. As controlled data are lacking, a topical review is distinct from 
the ECCO consensus guidelines and is intended to provide guidance in clinical areas where scientific 
evidence is lacking. An open call was announced to all ECCO members, following which 15 individuals 
were selected based on their expertise in the topic, and three subgroups were formed. 
Working Group 1 focused on withdrawal of 5-aminosalicyclates [5ASA; mesalazine, olsalazine, 
balsalazide, and sulphasalazine] with their major focus therefore on UC. Topics examined included: 
optimal duration of 5ASA treatment; timing/strategy for dose reduction; risks, benefits and timing of 
stopping treatment; success of re-treatment; factors associated with high risk of relapse on stopping; 
and optimal monitoring following withdrawal. Risks of 5ASA withdrawal in CD were also discussed. 
Working Group 2 focused on withdrawal of immunomodulators [IM; azathioprine, mercaptopurine, and 
methotrexate] including: risks, benefits, and timing of stopping IM monotherapy in UC and CD; risks, 
benefits, and timing of stopping IM when used in combination with biologic therapies in UC and CD; 
the evidence for a role for IM dose reduction; factors determining risk of relapse on stopping therapy; 
optimal monitoring following withdrawal; and success of re-treatment. 
Working Group 3 examined withdrawal of biologic therapy [primarily the approved TNF inhibitors; 
infliximab, adalimumab, golimumab] including: risks, benefits, and timing of stopping TNFi 
monotherapy in UC and CD; risks, benefits, and timing of stopping anti-TNF used in combination with 
IM in UC and CD; evidence for anti-TNF dose reduction or increasing dose intervals in patients in 
remission on treatment; factors determining risk of relapse on stopping therapy; optimal monitoring 
following withdrawal, and success of re-treatment. Data on outcomes after stopping other recently 
approved biologies, eg vedolizumab and ustekinumab, were also sought. 
The working groups performed a systematic literature search of their topic with appropriate key words, 
using Medline/Pubmed and the Cochrane database, as well as their own files. Discussions and 
exchange of the published evidence among the working party members and a preliminary voting round 
took place, followed by a revision of the statements. The working parties met in Barcelona on 15 
February 2017 to agree on the statements. Statements were accepted when 80% or more participants 
were in agreement, and were henceforth termed an agreed Current Practice Position. The group 
leaders and their respective working party wrote the final section for each subgroup. It is intended that 
the statements be read in context, with qualifying comments and not in isolation. The final text was 
edited for consistency of style by the steering committee and two members of the Guidelines 
Committee of ECCO who were not involved in the consensus. In several areas, the level of evidence 
is low, which reflects the paucity of randomised controlled trials. Consequently, where appropriate, 
expert opinion is included. 
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SECTION 1 —GENERAL CONSIDERATIONS 
Current Practice Position 1.1 
Before withdrawal or reduction of any maintenance IBD therapy is considered, an appropriate re-
evaluation of disease activity using a combination of clinical, biochemical, endoscopic/histological, 
and/or radiological techniques should be performed to inform the evaluation of risks and benefits of 
stopping. Disease history, severity, and extent are important factors to be taken into account. 
Current Practice Position 1.2 
Decisions on treatment withdrawal should be informed by patient preference. 
Current Practice Position 1.3 
Optimal monitoring following withdrawal of maintenance treatment has not been defined; however, 
monitoring of symptoms, inflammatory markers such as C-reactive protein/faecal calprotectin, and/or 
endoscopy/imaging for reassessment seem reasonable. 
There is good evidence that patients with subclinical disease activity are at much higher risk of relapse 
when any treatment is reduced or withdrawn. The specific evidence is reviewed relative to each class 
of medication, but it is agreed that re-evaluation of disease activity using techniques appropriate to the 
patient should be undertaken to ensure that counselling can be informed by a realistic estimation of 
the risks of relapse. A given risk of relapse over time may be acceptable to one patient but not to 
another; therefore the preference of the specific patient is important in formulating an exit strategy 
from treatment. 
After withdrawal of any therapy, patients require regular follow-up because recurrence of disease is 
common. Optimum surveillance in terms of timing of clinical, biochemical, and endoscopic follow-up 
has not been defined in prospective studies. It is acknowledged that disease may recur in the absence 
of clinical symptoms, so symptom-based monitoring alone is considered insufficient. A significant 
proportion of patients consider mild symptoms of relapse to be normal and even health care 
professionals often underestimate symptoms indicating a relapse.
5
 Even mild symptoms are 
associated with a reduced quality of life in IBD;
6,7
 and, as these symptoms may sometimes be 
associated with severe intestinal lesions putting the patient at risk of complications, a close follow-up 
of disease activity after withdrawing or reducing treatment is key to identifying disease flares at any 
early stage when they may be more likely to respond to therapeutic intervention. Complete mucosal
8-13
 
and, mainly in ulcerative colitis, histological healing
14,15
 are presently the best prognostic markers for 
risk of relapse in subsequent years. However, repeated colonoscopy with biopsies is not acceptable to 
patients and carries procedure-related risks and substantial costs. Biomarkers can therefore assist in 
identifying patients at risk of symptomatic relapse; these include C-reactive protein [CRP] and faecal 
biomarkers. 
16-18
 Studies have confirmed a significant association between CRP levels and the risk of 
relapse in patients with CD or UC.
19-25
 More data are available on the prognostic significance of faecal 
biomarkers such as calprotectin, lactoferrin, or faecal haemoglobin to predict relapse.
26-31
 Faecal 
calprotectin [FCP] concentration has been repeatedly validated as an indicator of endoscopic evidence 
of mucosal inflammation in UC and CD.
32-34 
Increased FCP is consistently able to predict the risk of a 
future flare, especially within the following 2-3 months.
35,36
 Although there is no clear consensus on 
how often FCP should be determined, intervals of 3 months after withdrawal seem reasonable in 
clinical practice.
37 
However, it is still a matter of debate if a rise in FCP levels during follow-up by itself 
provides sufficient reason for intensifying therapy or introducing new treatment. In this context, Lasson 
et al. evaluated whether pharmacological intervention guided by FCP prolongs remission in patients 
with UC.
38
 Although this approach did not result in an overall reduction of relapse, patients who were 
subject to the active intervention had fewer disease relapses as compared with patients in the control 
group, despite comparable FCP levels. These results offer some evidence that measuring FCP levels 
alone may be used to guide 5-ASA dosing and withdrawal. 
 
SECTION 2-WITHDRAWAL OF 5-ASA 
Benefits of long-term 5-ASA treatment 
Current Practice Position 2.1 
5-ASA maintenance therapy is generally safe and reduces the probability of relapse and the risk of 
colorectal cancer. 
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The efficacy of 5-aminosalicylic acid [5-ASA] in maintenance of UC remission is well established. A 
recent Cochrane meta-analysis confirmed that 5-ASA is superior to placebo for maintenance therapy 
in ulcerative colitis.
39
 The updated ECCO guidelines on UC treatment state that mesalazine 
compounds are the first-line maintenance treatment in patients responding to mesalazine or steroids 
[oral or rectal] .
40  
The Toronto consensus guidelines recommend, in patients with oral 5-ASA induced complete 
remission of mild to moderate active UC of any extent, continuing oral therapy of at least 2 g/day to 
maintain complete remission.
41
 Recent meta-analyses show that both oral and topical 5-ASA drugs 
are not associated with any greater number of adverse events than placebo. Adverse effects were 
commonly mild, including flatulence, abdominal pain, nausea, diarrhoea, and headache.
42,43
 Rare 
serious adverse effects of 5-ASA, such as nephrotoxicity, are described.
44 
Case-control studies have shown that regular, long-term use of 5-ASA significantly reduces the risk of 
colorectal cancer by up to 75% in UC patients.
45,46
 A 10-year cohort study demonstrated that 31% of 
UC patients who stopped or did not comply with 5-ASA therapy, developed colorectal cancer 
compared with only 3% who continued long-term treatment.
47
 Furthermore, several systematic reviews 
and meta-analyses of observational studies confirm the protective role of 5-ASA use against 
development of colorectal cancer and dysplasia.
48-50
 
Given the excellent safety profile of 5-ASA, the risks of stopping treatment therefore generally exceed 
the benefits in most UC patients. 
Optimal duration of treatment 
Current Practice Position 2.2 
In general, 5-ASA treatment should not be discontinued in patients with UC even during remission. 
The optimal duration of 5-ASA therapy is unclear. In most trials of maintenance therapy with 5-ASA, 
the endpoint is the absence of relapse or failure to maintain clinical remission after 6 to 12 months. 
Only a small number of retrospective studies have assessed the benefit of maintenance with 
sulphasalazine [SSZ] or 5-ASA in the longer term. In 1973, a study reported that maintenance 
treatment with SSZ 2 g/day continued to have a major effect at reducing relapse, even in patients 
treated for more than 3 years.
51
 However, another study reported no benefit of maintaining SSZ for 
patients symptom-free on treatment for more than a year.
52
 In a double-blind randomised controlled 
trial [RCT], 112 UC patients in remission for > 1year on 5-ASA or SSZ were randomised to oral 
mesalazine 1.2 g/day or placebo [treatment withdrawal] for 12 months.
53
 In patients with disease 
remission for 1-2 years, mesalazine appeared significantly more effective than placebo for preventing 
relapse at 12 months [mesalazine 23% and placebo 49%, p = 0.035]. For patients in remission for 
more than 2 years [51 patients], there was no difference in relapse rates [18% vs 26%, respectively]. 
Considering the benefits in terms of disease control and the prevention of colonic cancer, the general 
recommendation is therefore to continue 5-ASA treatments in the long term, even in patients in clinical 
and endoscopic remission. However, the recent update to the UC guidelines recognizes that 
intermittent therapy is acceptable in some patients with proctitis.
40
 The panel also considered that a 
discussion about stopping treatment might also be considered in some selected UC patients with: 1] 
limited disease extent [eg proctosigmoiditis]; 2] remission for several years; 3] history of a first or 
single disease flare only; and 4] not having required systemic corticosteroid therapy [recognizing that a 
primary goal of maintenance therapy is to avoid corticosteroid use]. 
Timing/strategy for dose reduction 
Current Practice Position 2.3 
In UC patients with high adherence to the drug, mild clinical course of the disease, low faecal 
calprotectin levels, and/or complete mucosal healing, 5-ASA maintenance dose reduction can be 
considered 
The ideal dosing of oral 5-ASA maintenance therapy has not been clearly defined. The ECCO UC 
guidelines suggest that the effective dose of oral 5-ASA to maintain remission is 2 g/day, and that for 
rectal treatment 3 g/week in divided doses may be adequate.
40
 Higher doses [greater than 2-2.4 
g/daily] are probably required for patients with low drug adherence, extensive colitis, and/or frequently 
relapsing disease.
42,54
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Data obtained from the Veterans Health system from 2001-2011, regarding 4452 UC patients with a 
median follow-up of 6 years, showed no difference in the long-term flare risk between low [2.4— 2.8 
g/day] vs high [4.4-4.8 g/day] doses of mesalazine, provided moderate to high levels of treatment 
adherence. However, among patients with low adherence, there was a significant reduction in the risk 
of flares with high dose maintenance (hazard ratio [HR] = 0.28, p = 0.003).
56
 In an Italian study, 
although no difference was found in relapse rates at 1 year on mesalazine 1.2 g compared with 2.4 
g/day, patients with extensive UC in the 2.4 g group remained in remission for a longer time than those 
in the 1.2 g group [143 vs 47 days, p < 0.005]. When the results for patients in remission at 12 months 
were analysed after stratifying for frequently relapsing disease [> 3 relapses/ year] vs less frequent 
relapses, 2.4 g/day also performed significantly better than 1.2 g/day [75% vs 33%, respectively].
57
 A 
recent RCT of 112 UC patients in remission showed that in patients younger than 40 years and/or with 
extensive disease, mesalazine 4.8 g resulted in an increased rate/duration of remission at 1 year 
compared with 2.4 g.
58
 
One further recent study, including 203 UC patients in remission, showed that 5-ASA dose reduction is 
more successful if a Mayo endoscopic subscore [MES] of 0 is achieved.
59
 The remission maintenance 
rate was higher with an MES of 0 compared with 1 [p = 0.007].
59 
Two recent RCTs, regarding 119 and 
91 patients with quiescent UC, showed that FCP of > 200 and > 300µg/g, respectively, can identify 
patients with a higher risk for a flare.
38,60
 Persistent histological activity also appears to predict risk of 
relapse in UC patients in clinical remission on treatment.
61
 Reduction to a maintenance oral 5-ASA 
dose of 2-2.4 g/daily or below, in the presence of a raised FCP or persistent endoscopic and/or 
histological inflammation, was therefore considered by the panel to be best avoided. 
Factors associated with high risk of UC relapse on stopping 5-ASA 
Current Practice Position 2.4 
There is heterogeneity in the risk of relapse after the discontinuation of 5-ASA maintenance in patients 
with UC. The risk of relapse with stopping 5-ASA maintenance is increased in patients with extensive 
colitis and history of frequent disease relapses. 
It is critical to establish predictors of the relapse risk after discontinuation of 5-ASA for individual 
patients. As already outlined, few studies specifically examine 5-ASA withdrawal. Relapse rates are 
higher in patients with left-sided or extensive colitis at diagnosis (hazard ratio = 1.46; 95% confidence 
interval [CI] = 1.01-2.10; p = 0.04) and initial haemoglobin level < 10.5 g/dL [hazard ratio = 0.43; 95% 
CI = 0.22-0.81; p = 0.01].
62 
The effect of disease extent was not seen as clearly in other studies, 
though again patients with distal colitis had a slightly better course.
63
 As patients with extensive 
ulcerative colitis or with frequent relapses may benefit from a higher dose of maintenance therapy,
64
 
withdrawal of 5-ASA when used as monotherapy should be avoided in this subgroup. A proportion of 
these patients will, however, require treatment escalation of maintenance treatment to either 
immunomodulator and/or anti-TNF therapy, and it is unclear whether continued 5-ASA in such patients 
adds much incremental therapeutic benefit. However, there may be additive benefits especially in 
terms of chemoprevention. 
Success of re-treatment with 5-ASA 
Current Practice Position 2.5 
In patients having stopped 5-ASA during a first successful course of oral corticosteroids for an acute 
flare, resuming 5-ASA after the control of the flare may be effective. 
Most UC patients receive 5-ASAs in order to induce and maintain remission.
65
 There are no published 
data on the efficacy of resuming 5-ASA for a flare after stopping the drug while in remission. However, 
a large proportion of patients will experience a flare despite 5-ASA requiring treatment with oral 
glucocorticocoids [GCS], thus warranting a decision about how to proceed in terms of maintenance 
treatment once remission has been achieved. In an observational study of 143 mild-to-moderate UC 
patients naive to immunosuppressive therapy, treated for the first time with oral corticosteroids, 52 
[36%] patients achieved clinical remission after weaning from the GCS. Of these, 35 were restarted on 
5-ASA [minimum dose 2.4 g/day] as maintenance therapy
66
 ;22 patients [63% of those who 
recommenced 5-ASA] remained in remission on 5-ASA after 1 year but only 7 [20%] at 10 years' 
follow-up These data suggest that in this setting, 5-ASA is insufficient for long-term maintenance in 
most patients. Only male gender and short duration of disease could be identified as predictive factors 
of the time-to-relapse in this group of patients. Similar findings were reported in a letter describing 13 
patients with moderate to severe UC, who were restarted on 5-ASA 4.8 g/day once GCS had been 
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tapered to 20 mg and they were in clinical remission. Nine [69%] patients remained in remission for a 
median of 20 weeks after steroids were discontinued.
67
 
Risks of 5-ASA withdrawal in Crohn's disease 
The scientific evidence regarding the efficacy of 5-ASA in CD patients is in sharp contrast to clinical 
practice. Several systematic reviews have concluded that the role of 5-ASA in CD, to either induce 
remission or prevent relapses, is no better than placebo or, at best, remains uncertain.
68-70
 
Accordingly, international guidelines do not recommend the use of 5-ASA in CD.
71
 However, in 
population-based cohorts more than 50% of CD patients at some point in their disease course receive 
5-ASA for long periods. The consequence of withdrawal of 5-ASA in CD patients remains unclear and, 
in two cohorts, some kind of 5ASA-dependence was described.
72,73 
 
SECTION 3-WITHDRAWAL OF IMMUNOMODULATORS [AZATHIOPRINE, MERCAPTOPURINE 
OR METHOTREXATE] 
Withdrawal of IM when used as monotherapy 
Current Practice Position 3.1 
There is a cumulative risk of relapse with time after withdrawal of IM monotherapy in both CD and UC, 
and it is estimated that approximately 30% of patients relapse by 2 years and 50-75% relapse by 5 
years. 
Current Practice Position 3.2 
It is reasonable to re-consider, in conjunction with the patient, the risks and benefits of continued IM 
monotherapy for IBD patients treated for 3-4 years if there is no evidence of continuing disease 
activity. 
Current Practice Position 3.3 
Factors predictive of relapse following withdrawal of IM monotherapy include elevated markers of 
subclinical disease activity [in both CD and UC] and disease extent/localization [peri-anal disease in 
CD, extensive disease in UC]. 
ECCO guidelines support the use of thiopurine immunomodulators (azathioprine [AZA] and 
mercaptopurine [MP]) as effective maintenance therapy for both CD and UC.
40,71
 In addition, the 
guidelines recognize that methotrexate [MTX], used as an immunomodulator, is effective for remission 
maintenance in CD.
71
 The CESAME cohort study has, however, highlighted the risks associated with 
long-term use of thiopurine IM in IBD patients, including elevated risk of lymphoproliferative disorders, 
non-melanoma skin cancers, myeloid disorders, and urinary tract cancers.
1-4
 Therefore periodic re-
evaluation of the risk/benefit ratio of continued treatment with these agents seems important. Whereas 
some studies have shown a reduction in the risk of colorectal neoplasia in UC patients treated with 
thiopurines,
74
 no convincing reduction in colorectal cancer with thiopurine IM use was oberved in a 
recent meta-analysis.
75
 Therefore the only trade-off for the long-term risks of treatment may be a 
sustained reduction in the risk of disease relapse. 
Early studies suggested a low risk of relapse following azathioprine withdrawal in CD, and therefore a 
traditional practice has evolved of considering stopping if a patient remains in remission for 3-4 
years.
76
 Subsequent studies have not provided strong evidence for this 3-4 year 'cut-off'. Based on 
extrapolation from transplant data, it seems likely that the risks of neoplasia with thiopurine treatment 
are related to duration of exposure and only begin to accumulate significantly after several years of 
therapy. 
In CD, an initial multicentre double-blind study of AZA-treated patients, in clinical remission for at least 
3.5 years, observed that 3/40 patients who continued treatment relapsed by 18 months compared with 
9/43 patients who stopped [based on the non-inferiority design, the authors failed to reject the 
hypothesis that placebo was inferior to AZA continuation].
77
 At 1,3, and 5 years after withdrawal, 
cumulative risk of relapse was 14%, 53%, and 63%, respectively. Three subsequent RCTs also show 
higher relapse rates in the drug withdrawal arm, from 8% to 25% at 6 months, 17% to 53% at 12 
months, 21% to 31% at 18 months, and 31% at 24 months.
78-80
 In a subsequent meta-analysis of 
studies in CD, thiopurine IM continuation decreased the risk of relapse at 6, 12, and 18 months with 
pooled odds ratios of 0.22, 0.25, and 0.35, respectively, and a pooled odds ratio of 0.53 at 5 years 
[based on data from two studies].
81
 No prospective studies of MTX withdrawal in CD have been 
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reported, but retrospective studies report a high risk of relapse [approximately 80% at 12 months] in 
patients stopping therapy.
82
 There is significant heterogeneity between studies regarding the duration 
and definition of remission preceding IM withdrawal. It is therefore likely that if only patients with 
sustained true biological remission [i.e symptomatic, biochemical, and endoscopic/radiological 
remission] were studied, the risk of relapse would be lower. 
There are fewer studies of stopping IM monotherapy in UC. Only one multicentre double-blind RCT of 
withdrawal of AZA in UC patients has been reported. For UC patients in short-term remission with 
AZA, 1-year relapse rates of 59% were observed with AZA withdrawal and 36% with continued 
therapy [p = 0.039].
83 
In a multicentre retrospective study, after AZA withdrawal one-third of UC 
patients relapsed within 12 months, half within 2 years, and two-thirds within 5 years.
84
 Cohort studies 
reported discrepant relapse rates after IM withdrawal: from 11% to 77% at 12 months, 21% to 100% at 
24 months, 43% to 65% at 5 years, and up to 87% with longer follow-up periods.
85,86
 
A recent systematic review has summarised the predictive factors for relapse in both CD and UC after 
thiopurine IM withdrawal.
87
 These are summarised in Table 1. Age may be a key consideration in 
assessing the risk/benefit trade-off when considering stopping IM therapy. The recently published 
BERENICE study modelled mortality risk in CD patients according to IM use, age, and disease 
extent.
88
 The model favoured sustained IM treatment in CD patients with extensive colitis, irrespective 
of age [estimated life-years gained 0.19; 95% CI = 0.06-0.24]. However, in patients without extensive 
colitis, the mortality model favoured stopping IM treatment in men > 40 years and women > 45 years. 
It is notable that the vast majority of deaths in CD patients [> 96%] are unrelated to disease or 
treatment. 
Table 1. Factors associated with higher relapse rates in CD [left column] and UC [right column] 
following withdrawal of thiopurine IM monotherapy. Based onTorres et al. 2015.
87
 
Factors associated with higher CD relapse risk Factors associated with higher UC relapse risk 
Elevated C-reactive protein level
23,77,85
 Increased leukocyte count
23,91
 



















Short duration of remission
76
 Number of relapses on azathioprine
84,91
 
Shorter time since latest steroids
77
 Shorter duration of azathioprine
84,91
 
Higher dose of azathioprine
79
 Longer time from diagnosis to azathioprine
91
 







Stopping IM when used as a part of combination therapy 
Current Practice Position 3.4 
The rate of relapse [in the subsequent 2 years] following IM withdrawal in CD patients treated with 
combination therapy for > 6 months is probably not greater than with continued combination therapy. 
Relapse rates may be higher in UC, but data are limited. 
Current Practice Position 3.5 
Higher infliximab trough levels at withdrawal are associated with lower rates of relapse following IM 
discontinuation. 
Current Practice Position 3.6 
IM withdrawal in patients treated in combination with anti-TNF therapy may be inappropriate in 
patients with high-risk/refractory disease or in patients 'at risk' of biologic failure. 
RCT have shown that combination therapy with infliximab [IFX] and concomitant azathioprine [AZA] 
results in significantly higher rates of clinical remission and mucosal healing as compared with 
monotherapy in both CD and UC.
92,93
 However, as already outlined, an increased infection and 
malignancy risk has been demonstrated in IBD patients receiving immunomodulators [IM]. The risk of 
neoplasia related to anti-TNF therapy remains more uncertain, and is being addressed by large 
prospective observational studies such as I-CARE. Therefore, there is interest in de-escalation of 
combination therapy once remission is achieved and, given the relative efficacy and safety of the two 
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agents, stopping IM treatment is often the favoured approach. 
In two randomised trials, the proportion of CD patients in clinical remission who experienced a relapse 
was similar in those stopping IM compared with those continuing combination therapy with anti-
TNF.
94,95
 Retrospective cohort studies in CD have shown similar findings.
96,97
 Only one study has 
reported outcomes in UC. This retrospective analysis on IM withdrawal from combination therapy with 
IFX found a significantly higher rate of UC relapse in the discontinuation cohort [12% vs 3% trimesters 
with clinical flare, p = 0.049]. The mean time to relapse after IM withdrawal was 7 months [compared 
with 17 months in patient who continued combination therapy] .
98
 
Considering that the average duration of combination therapy in these studies was 1-2 years, it 
therefore appears that in CD patients receiving combination therapy with IFX, continuation of IM 
beyond this time frame probably offers no additional benefit over scheduled IFX monotherapy. 
However in some trials, continued combined therapy was associated with higher median IFX trough 
and decreased CRP levels. Thus it is reasonable to combine IM and biologics for at least 1 year, until 
sustained clinical and endoscopic remission is reached, with the decision on IM discontinuation also 
guided by the trough level of biologic at this time. In high-risk patients with extensive/complicated 
disease, where a disease relapse could have important clinical consequences [eg risk of extensive 
resection, permanent ostomy, or short small bowel syndrome], it is reasonable to decide to continue 
combination therapy indefinitely, balancing the risk for disease progression and the potential side 
effects of long-term combination therapy on an individual basis. 
IM dose reduction vs withdrawal 
A single small randomised study on azathioprine dose reduction [compared with continuation at full 
dose or withdrawal in IBD patients in remission on combination treatment for 1 year] has reported that 
the positive impact of IM on infliximab drug levels can be sustained with a 50% dose reduction. No 
increase in the risk of relapse with dose reduction was observed, but the study may have been 
underpowered to detect a difference in clinical outcomes.
99
 The potential risks and benefits of IM dose 
reduction in place of stopping require further evaluation. 
Factors predictive of relapse following IM withdrawal 
Factors predictive of relapse should be considered before stopping IM, and these are similar to those 
outlined in Table 1. Shorter duration of combination therapy before withdrawal and lower trough 
biologic levels at the time of withdrawal may be additional specific factors to consider in this particular 
context. Certain patients tend to make neutralising antibodies to therapeutic monoclonal antibodies, 
and patients who are known to have anti-drug antibodies consistently to their current or previous anti-
TNF agents may be at increased risk of treatment failure following IM withdrawal. Depending on the 
context, continued combination therapy may be a better option for this group of patients. 
Success of re-treatment, concept of drug holidays 
Current Practice Position 3.7 
Studies on re-treatment with IM following relapse generally report good rates of clinical response and 
remission. However, only short-term follow-up is reported, and potential long term consequences 
require evaluation in further studies. 
In one study of withdrawal of IM monotherapy in CD patients, only 1/23 patients who relapsed and 
were re-treated by AZA did not achieve remission. A median duration of remission of 2 8 months with 
the second course of IM was reported.
89
 In a larger multicentre retrospective study, re-introduction of 
thiopurine was successful in 31/42 [74%] of CD patients with moderate to severe relapse,
23 
a number 
requiring either anti-TNF therapy or surgical resection. Interestingly, both the risk of relapse and 
success of re-treatment were greater in UC than CD in the same study; 22/24 [92%] of UC patients re-




The concept of drug holiday has emerged in the treatment of other immune-mediated disorders where 
stopping therapy for a defined period is suggested to reduce the risk of infectious or other 
complications [eg 6-month drug holiday from natalizumab following 12-24 months of treatment in 
relapsing and remitting multiple sclerosis]. Spontaneous regression of IM-related neoplasia such 
melanoma and lymphoma following withdrawal of immunosuppressants is well described.
100
 It is 
possible that allowing periodic immune reconstitution by stopping or reducing the intensity of immune 
suppression may moderate some of the risks of long-term IM therapy. However, there is no evidence 
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currently to support the concept of drug holidays from IM therapy in IBD. The risks and benefits should 
be evaluated in prospective studies. 
 
SECTION 4-WITHDRAWAL OF ANTI-TNF AGENTS 
Risks, benefits, and timing of stopping anti-TNF used as monotherapy or in combination with 
IM in UC and CD 
Current practice position 4.1 
The risk of relapse after anti-TNF withdrawal is between 30-40% at 1 year, and greater than 50% 
beyond 2 years. 
Current practice position 4.2 
The clinical benefits of anti-TNF withdrawal [lower infection or cancer risk] are at present theoretical, 
as no controlled study has been performed. 
The use of anti-TNF therapy is associated with several clinical benefits in IBD, such as higher mucosal 
healing, fewer hospitalisations and surgical procedures, and improved quality of life.
8,101-103
 However, 





 Although some decision analysis models have established that TNFi agents 
are cost-effective,
106
 it is not so certain that they remain so in the long run. However, the concerns 
related to discontinuation of TNFi in IBD patients include the risk of relapse, the possible loss of 
efficacy when the drug has to be restarted, the risk of infusion reactions or other adverse events at re-
treatment, and, finally, the worries over losing future—and limited—medical treatment options.
107
 
The aim of a recent study was to systematically review and perform a meta-analysis of the risk of 
relapse after discontinuation of TNFi in IBD patients.
108
 In total, 27 studies [21 infliximab, 6 inflixi-
mab/adalimumab] were included.
108
 The overall risk of relapse after discontinuation of anti-TNF 
therapy was 44% for CD [95% CI = 36-51%; P = 79%; 912 patients] and 38% for UC [23-52%; P = 
82%; 266 patients]. In CD, the relapse rate was 38% at 6 months after discontinuation [short term], 
40% at 12 months [medium term], and 49% at > 25 months [long term]. In UC, 28% of patients 
relapsed at 12 months [and 36% at medium term, eg 12-24 months after the discontinuation of anti-
TNF therapy]. 
Although the overall relapse rate after discontinuation was somewhat higher in CD than UC patients 
[44% vs 38%], some of the UC studies included had shorter follow-up.
108
 Some studies, which 
included both CD and UC patients, found a non-significant trend for longer persistence of remission 
after IFX discontinuation in patients with UC.
107
 However, consequences of the relapse may be more 
serious in UC: the colectomy rate after stopping anti-TNF in remission was around 10% within 1 year 
after TNFi withdrawal.
109
 Obviously, these differences should be confirmed in adequately controlled 
studies. 
Experience with a longer follow-up period [> 1 year] is very limited. The risk of relapse > 25 months 
after discontinuing anti-TNF agents in the present meta-analysis was approximately 50%. Some 
studies followed up the patients for up to 10 years.
107,110-112 
The relapse rate beyond 5 years reached 
70%.
111,112
 Therefore, if followed for long enough, most patients in whom anti-TNF therapy has been 
stopped will eventually relapse. On the other hand, a minority of patients may achieve 'indefinite' 
remission without treatment. 
In summary, there remains a lack of high quality studies in this area. We need more studies, ideally 
randomised controlled trials, to compare the TNFi discontinuation strategy with a control group where 
the TNFi is maintained, and where the natural disease course with standard TNFi treatment [including 
the well-known loss of response to these drugs] is ascertained. 
Factors determining risk of relapse on stopping therapy 
Current practice position 4.3 
Patients in deep [clinical, biological, and endoscopic] remission probably have a lower risk of relapse 
after anti-TNF discontinuation. Therefore, anti-TNF withdrawal should probably be considered only in 
patients in longstanding stable clinical, biological, and endoscopic remission. 
Current practice position 4.4 
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Patients with previous need for anti-TNF dose escalation seem to be at high risk of relapse after 
discontinuation. 
Current practice position 4.5 
Maintenance of immunomodulator treatment after anti-TNF discontinuation seems to reduce the risk of 
relapse. 
A recent review systematically evaluated the factors associated with the risk of relapse after TNFi 
discontinuation in IBD patients, in order to help the clinician to decide whether and when these drugs 
can be stopped.
113
 These are summarised in Table 2. 
Mucosal healing is often perceived as a key element and deserves specific comments. Several 
authors have demonstrated that mucosal healing in CD is associated with lower rates of abdominal 
surgery and hospitalisation
102
 and with longer relapse-free survival during ongoing TNFi therapy.
8,101
 
Accordingly, several of the studies
109-111,116,127 
included in a previous meta-analysis showed that, when 
anti-TNF treatment was stopped based exclusively on achievement of clinical remission [without taking 
into account endoscopic remission], 42% of CD patients relapsed during the following year.
108
 
However, if patients discontinued TNFi agents after achieving not only clinical but also endoscopic 
remission, the relapse rate at 1 year decreased to 26%. Similar differences were observed for UC 
patients: relapse rates were 50% and 33% after discontinuation of therapy based exclusively on 
clinical remission and on endoscopic remission, respectively. It should be noted, however, that not all 
studies demonstrate a correlation between mucosal healing at discontinuation and the frequency of or 
time to clinical relapse, in either CD or UC patients.
128-131,133
 
When considered in isolation, none of the risk factors outlined in Table 2 is able to accurately predict 
the probability of relapse after discontinuation of TNFi therapy. Patients with a high [or low] risk of 
relapse could perhaps be best identified using a combination of clinical, biological, and endoscopic 
markers. The multivariable analysis in the STORI trial revealed several risk factors for relapse: male 
sex, absence of surgical resection, high leukocyte count, low haemoglobin level, high CRP, elevated 
FCP, high IFX trough levels, and no mucosal healing.
116
 Two different relapse-predicting models have 
been developed with the STORI trial data: those models could identify a subgroup of patients with a 
low [15%] risk of relapse within 1 year. The results suggest that simple parameters may be used to 
identify a subgroup of patients with a low risk of relapse, in whom withdrawal of TNFi treatment can be 
considered. These parameters and models still need to be validated, and their useability in a 'real-
world' setting remains to be established.
133
 
Lack of concomitant IM medication [eg thiopurines and methotrexate] after stopping TNFi was 
associated with a higher rate of relapse in some studies.
108
 Although previous failure of IM was 
associated with a lower beneficial effect,
117
 the protective effect of IM drugs has been confirmed, even 
if they were previously ineffective for controlling IBD. A recent and very large study, including more 
than 1000 patients,
121
 showed that the lack of IM maintenance treatment after TNFi was stopped was 
a predictive factor for relapse after discontinuation of anti-TNF therapy. However, other studies could 
not confirm this beneficial effect of co-treatment with immunosuppressive drugs for the prevention of 
relapse after discontinuation of TNFi.
134 
Evidence for anti-TNF dose reduction or increasing dose intervals in patients in remission 
Current practice position 4.6 
Anti-TNF dose de-escalation seems to have little impact on disease remission provided the trough 
level of the drug remains within an appropriate target window. 
Current practice position 4.7 
A state of deep remission [clinical, biological, and endoscopic remission] probably decreases the risk 
of relapse after dose de-escalation. 
Current practice position 4.8 
In patients having needed a previous dose escalation due to loss of response, subsequent dose de-
escalation is associated with a high rate of relapse. 
Optimal dosing of biologics is especially important because of the risk of treatment immunogenicity, 
adverse effects, and low cost-effectiveness due to high cost. There are a few studies investigating the 
impact of TNFi reduction [by dose reduction or increasing dose intervals] on maintenance of disease 
remission. 
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In the landmark TAXIT trial, patients in clinical remission with IFX trough levels [TLs] > 7 µg /mL had 
dose de-escalation to a target trough concentration [TC] of 3-7 µg/mL. De-escalation was by reducing 
dose to 5 mg/kg [if previously on 10 mg/kg] or increasing the interval between IFX infusions by 2 
weeks [to a maximum interval of 12 weeks]. Of 72 patients with TLs > 7 µg/ml, 93% achieved the 
target range after dose reduction. This resulted in a 28% reduction in drug cost [p < 0.001] without 
change in the proportion of patients in remission or in CRP concentration.
135
 Another pilot trial 
indicates that CD patients in deep remission may increase the dose interval of IFX to 10 weeks without 
risking loss of response, provided that levels of FCP are maintained in the normal range.
136
 
In another prospective study of 20 adult IBD patients who achieved deep remission after treatment 
with IFX at 10 mg/kg every 8 weeks for secondary loss of response, IFX dose was decreased by 1 
mg/kg at each infusion to a dose of 5 mg/kg, or to get a target trough concentration of 3-7 µg/mL. No 
significant change was observed in the mean Crohn's Disease Activity Index [CDAI] scores and FCP 
levels for CD, or the Mayo score for UC, before and during follow-up after the therapeutic de-
escalation.
137
 However, de-escalation in patients having previously required dose escalation may be 
more hazardous: a relatively high proportion of patients seem to relapse after such treatment de-
escalation in the short term,
138-140
 and only one-third of patients who relapse after de-escalation regain 
remission with 're-escalation'.
140
 Likewise, eight of 24 patients had lost response after a median follow-
up of only 7 months after 'de-intensification' of the TNFi therapy in a Spanish study.
141 
 
Table 2. Factors associated with altered risk of CD relapse following anti-TNF withdrawal 
Demographics Age [at diagnosis] Conflicting reports
114,115
 
 Gender Conflicting reports, possible increase in males
116
 
 Smoking Increased risk of relapse in active smokers
117
 
Clinical factors Disease duration Uncertain 
 Disease location Higher risk for ileocolonic than isolated ileal disease
118 
Higher risk if associated fistulising peri-anal disease
117
 
 Previous surgery Conflicting reports
116,115
 
 Complicated disease Possible increased risk if previous stricture/fistula
114
 
 Previous dose escalation Increased risk if required previous dose optimisation
120
 
 Concomitant IM Absence of IM—increased relapse risk
117,121
 
 Mucosal healing Reduced risk of relapse in most studies
115,116
 
Laboratory markers Haemoglobin Hb < 14.5 g/dL may increase the risk
116
 
 Leukocyte counts White cell count > 6 x 10
9
/L may increase the risk
116
 
 C-reactive protein Raised CRP on withdrawal—increased relapse risk
116
 











Immune factors Mucosal cytokines Elevated TNF/IL17-A—increased relapse risk in CD
123
 
Microbial factor Firmicutes Decreased counts may confer increased risk
124
 
 E Prausnitzii Decreased counts may confer increased risk
124
 
Genetic markers NOD2/CARD 15 Not predictive
125
 




Stopping biologies in peri-anal disease and other particular situations 
Current practice position 4.9 
Patients with peri-anal fistulas with response to anti-TNF therapy have a higher risk of relapse on 
withdrawal compared with luminal CD, and anti-TNF discontinuation is not generally recommended in 
this population. 
Current practice position 4.10 
In the setting of postoperative prophylaxis, anti-TNF withdrawal may be associated with higher risk of 
recurrence. 
Current practice position 4.11 
Discontinuation of anti-TNF in an IBD patient in remission, during the second trimester of pregnancy, 
appears safe for the mother and the newborn. 
Current practice position 4.12 
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The role of anti-TNF treatment in pouchitis and the impact of its withdrawal are not yet defined. 
Fistulising peri-anal disease 
Few studies specifically assessed the risk of relapse of fistulising peri-anal CD after discontinuation.
108
 
Domenech et al. showed that in peri-anal disease, early relapse was the rule after stopping IFX 
treatment, with only one-third of patients maintaining remission at 1 year.
142
 A major drawback of this 
study was that the response to IFX was only measured in terms of the physical examination because 
of its retrospective design, and imaging techniques were not systematically performed.
143
 It is well-
known that peri-anal disease is often active despite external closure of fistulas
144
; in fact, patients with 
complex fistulas often need long-term treatment, and it has been suggested that response to TNFi 
treatment in peri-anal disease should be evaluated by imaging techniques rather than by physical 
examination alone.
143,145
 In a similar study, 58% of patients with luminal CD remained in corticosteroid-




CD commonly recurs after intestinal resection.
147
 It was recently demonstrated that administration of 
TNFi after intestinal resection in patients with CD effectively reduces postoperative recurrence.
148 
Consequently, a clinically relevant question is whether stopping TNFi treatment after some time [eg 1 
year after surgery in patients in remission] leads to recurrence. Regueiro et al. randomly assigned 24 
patients with CD who had undergone ileocolonic resection to receive IFX or placebo for 1 year,
149
 and 
demonstrated that IFX prevented endoscopic recurrence. At the end of the trial, 11 patients were 
offered open-label continuation of IFX; eight of the 11 patients elected to stop the drug and all eight 
patients had endoscopic recurrence at 1 year. In another study, 12 patients who started IFX 
immediately after surgery were still free of clinical and endoscopic recurrence of CD 3 years later.
150
 
However, discontinuation of IFX led to endoscopic recurrence after 4 months in 10 of 12 patients 
[83%]. Fortunately, remission was achieved after re-treating all 10 patients with IFX. Finally, in a 
recent postoperative study, nearly three-quarters of the IFX patients stopped treatment at 1 year after 
resection while in complete endoscopic remission.
151
 All of these patients subsequently experienced 
endoscopic recurrence and most required additional surgery. 
Pregnancy 
The use of TNFi agents after the second trimester leads to fetal intra-uterine exposure.
152
 To limit this 
exposure, it is generally recommended to discontinue the treatment around gestational Week 30 or 
even earlier.
153
 This strategy has proven safe for the newborn.
154 
However, it is unclear whether it is 
also safe for the mother [that is, whether it is associated with an increased risk of relapse of IBD]. 
The course of IBD in pregnant women who stopped taking TNFi agents was recently assessed.
155
 
Treatment was discontinued in patients with quiescent disease before gestational Week 30. In those 
taking IFX, 12 [71%] discontinued treatment, and all patients remained in remission. Since all the 
patients taking adalimumab were in remission, they all discontinued treatment before gestational 
Week 30; relapse was recorded in two patients, both of whom were receiving an escalated dose of 
TNFi. All patients who resumed treatment remained in remission during follow-up. In a further recent 
study, the same authors evaluated the maternal safety of discontinuing TNFi in the second trimester 
by comparing relapse between women who stopped and who continued TNFi.
156
 Patients in remission 
around gestational Week 20 stopped TNFi therapy before Week 25 [study group, 32 patients]. Those 
not in remission around Week 20 continued TNFi until at least Week 30 [control group, 22 patients]. In 
the study group, two patients relapsed at Weeks 30 and 36, respectively, after stopping TNFi therapy 
in Week 22, whereas in the control group one patient relapsed. The differences were not statistically 
significant. There were no differences in birthweight, gestation period, congenital abnormalities, or 
APGAR score between the study group and the control group. Therefore, discontinuation of anti-TNF 
treatment in the second trimester of pregnancy in IBD women in sustained remission seems safe for 
the mother in terms of disease control and risks related to resumption of treatment. 
 
Pouchitis 
In recent years, TNFi therapy administered for the medical management of chronic refractory pouchitis 
has yielded encouraging results.
157
 However, data regarding optimal duration of administration are 
lacking.
158
 The only study to report on the long-term outcome of patients with chronic refractory 
pouchitis after discontinuation of successful TNFi therapy indicates that IFX could be discontinued in 
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those who maintain complete clinical response after 1 year of therapy.
159
 These results need to be 
confirmed in future studies. 
Optimal monitoring following withdrawal of biologic therapy 
Current practice position 4.13 
Due to high risk of relapse, patients stopping anti-TNFs should have closer follow-up clinically and with 
biomarkers. 
Current practice position 4.14 
Most relapses occur within 6-12 months after withdrawal, and a more intensive follow-up should 
therefore be applied during the first year. 
Current practice position 4.15 
After anti-TNF withdrawal, an elevation of FCP [and to a lesser extent CRP] usually occurs a few 
months before clinical relapse. 
Current practice position 4.16 
Strict clinical evaluation with frequent CRP and FCP measurements should be performed after anti-
TNF discontinuation. Larger prospective studies are needed to determine the optimal interval for 
measuring FCP levels to predict relapse. 
Current practice position 4.17 
Elevation of FCP or CRP values after anti-TNF discontinuation should trigger prompt re-testing, and if 
elevated tests are confirmed, the patient should be carefully reassessed, preferably with endoscopy 
and/or imaging. 
Many of the patients in whom TNFi therapy is interrupted will, over time, experience endoscopic 
relapse, which in turn leads to clinical relapse.
159
 A larger proportion of relapses occur within 6-12 
months after withdrawal and a decreasing proportion is observed thereafter. Therefore, more intensive 
follow-up is probably recommended during the first year of follow-up after TNFi withdrawal. 
In a STORI sub-study, the usefulness of close monitoring of CRP levels to predict relapse of CD after 
discontinuation of IFX was evaluated
160
: patients were monitored every 2 months until 18 months of 
follow-up or clinical relapse. CRP and FCP levels were found to be highly variable, regardless of the 
occurrence of relapse. However, a consistent rise in CRP was observed in the 4 months before 
relapse, and CRP values > 5 mg/L were associated with relapse in the short-term [hazard ratio = 4]. 
Similarly, FCP increased in the 4 months before a relapse, and FCP > 250 µg/g was associated with 
relapse in the short term [hazard ratio > 6]. 
In a more recent study, prospectively enrolled IBD patients in clinical, endoscopic, and FCP-based [< 
100 µg/g] remission after more than 1 year of TNFi therapy were followed for 12 months after 
discontinuation.
161
 During follow-up, 31% of patients relapsed; they had shown constantly elevated 
FCP for a median of 94 days before relapse. A significant increase in median FCP was seen 2, 4, and 
6 months before endoscopic relapse. In contrast, stable, normal FCP during follow-up was highly 
predictive of clinical and endoscopic remission. 
Larger prospective studies are needed to determine the optimal interval for measuring the markers in 
prediction of relapse, as well as to determine the benefit of re-starting the treatment based solely on 
elevated/rising FCP during follow-up.
161 
Efficacy and safety of re-treatment with the same anti-TNF after relapse 
Current practice position 4.18 
Resuming the same anti-TNF in patients who relapse following anti-TNF withdrawal for sustained 
remission is usually safe and effective. 
Current practice position 4.19 
Immunomodulator co-treatment decreases the risk of treatment failure and infusion reactions after re-
treatment with the same anti-TNF Therefore, co-treatment with immunomodulators is recommended if 
tolerated. 
A recent meta-analysis assessed the response to retreatment with the same TNFi, following relapse 
Published in: Journal of Crohn's and Colitis, 2017,1-15 doi:10.1093/ecco-jcc/jjx101 




 Re-treatment with the same TNFi drug induced remission in 80% of 
IBD patients [95% CI = 68-91%; I
2
 = 86%; 290 patients].
107,109,116,128,130,132,162,163
 The results were 
similar in CD and UC. The tolerance to retreatment was also good in the STORI trial.
116
 These results 
contrast with the notion that drug 'holidays' have historically been associated with a higher risk of 
immunisation resulting in hypersensitivity reactions to the drug and loss of effect.
164
 A possible 
explanation for this finding could be the fact that in most studies, TNFi agents were initially given on a 
scheduled maintenance basis rather than on demand, a practice that was customary in the past.
159 
Obviously, the high efficacy of re-initiation of anti-TNF drugs may reflect the fact that these patients 
are a selected group, previously identified as anti-TNF responders. Such a favourable outcome 
following re-treatment of relapsing patients, after transient discontinuation of maintenance therapy with 
TNFi drugs, has been suggested in studies on rheumatoid arthritis
165,166
 and ankylosing spondylitis.
167
 
Longer-term follow-up in CD indicates that up to 6 years after resuming infliximab, only 30% of the 
patients experienced a secondary failure. 
A key aspect could also be the concomitant IM during drug holidays, which has been associated with 
higher efficacy and less acute infusion reactions.
158,168
 A recent study evaluated a group of patients 
who required re-treatment with IFX because of a clinical relapse after at least 6 months of 
discontinuation of the first treatment.
162 
Infusion reactions were recorded in 24% of patients, of whom 
17% discontinued treatment owing to severe reactions. Patients who maintained IM during the holiday 
between the two IFX treatments had significantly fewer re-infusion reactions. Before resuming the 
same TNFi treatment, anti-drug antibodies levels are usually low or undetectable, and cannot predict 
efficacy or safety of re-treatment. On the contrary, low trough levels and occurrence of anti-drug 
antibodies early after resuming the treatment are associated with a high risk of no response, loss of 
response, and infusion reaction.
169 
SECTION 5-CONCLUSIONS 
The likelihood of relapse with stopping treatment varies between the different classes of IBD 
medication. Although indefinite treatment with 5-ASA is safe and generally recommended [in UC], 
there is a strong rationale for addressing the potential to stop or reduce therapy with IM and TNFi 
drugs, especially when used in combination. In general, patients in clinical, biochemical, and 
endoscopic remission are more likely to remain well when treatments are stopped, and this is probably 
a condition before considering an exit strategy. Factors associated with an altered risk of relapse on 
withdrawal are useful in selecting patients likely to relapse early when off treatment. Strategies to 
monitor and allow early identification of relapse are a key consideration. In general, re-introduction of 
the same treatment is usually, but not always, successful. However, some patients with 'high-risk' 
disease should be counselled against discontinuation. Ultimately, the decision to stop a treatment 
needs to be tailored to the individual patient and the decision to stop or reduce taken in a shared way. 
Based on their review of the current published literature, the contributors identify several research 
questions that should be the subject of future investigation, and these are summarised in Table 3. 
Further randomised controlled studies to compare withdrawal of treatment with standard maintenance 
are required. In this respect, the SPARE study [CD], the STOP IT study [CD], the BIOSTOP study 
[UC], and the EXIT study [UC and CD] will add greatly to the evidence. 
Table 3. High priority research questions about treatment withdrawal for future study 
General What is the role of noninvasive markers such as FCP or imaging eg small bowel ultrasound in 
identification of 'pre-clinical' disease 
relapse in the asymptomatic patient 
What is the optimal monitoring strategy following withdrawal of therapy 
5ASA Is there an increased risk of relapse with stopping 5ASA in patients who have required 
escalation to IM and/or TNFi therapy Prospective study of 5-ASA discontinuation in CD which 
incorporates biochemical markers, e.g FCP, to identify factors which predict CD relapse 
IMM Is there a role for IM dose reduction rather than withdrawal in stable patients in remission on IM 
monotherapy or in combination 
with a biologic 
Prospective data on outcomes of MTX withdrawal in CD following remission are needed 
The risks and benefits of planned IM drug holidays to allow immune reconstitution should be 
explored 
Biologics Data on outcomes following vedolizumab and ustekinumab withdrawal and success of re-
treatment are required The global benefit/risk profile of cycles of biologic treatment vs continuous 
treatment should be prospectively assessed Further controlled studies on TNFi withdrawal 
and/or dose de-escalation are needed 
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